Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014). This Registered Report describes the proposed replication plan of key experiments from "Diverse somatic mutation patterns and pathway alterations in human cancers" by Kan and colleagues published in *Nature* in 2010 (Kan et al., 2010). The experiments to be replicated are those reported in Figures 3D-F and 4C-F. Kan and colleagues utilized mismatch repair detection (MRD) technology to identify somatic mutations in primary human tumor samples and identified a previously uncharacterized arginine 243 to histidine (R243H) mutation in the G-protein α subunit GNAO1 in breast carcinoma tissue. In Figures 3D-F, Kan and colleagues demonstrated that stable expression of mutant GNAO1_R243D conferred a significant growth advantage in human mammary epithelial cells, confirming the oncogenic potential of this mutation. Similarly, expression of variants with somatic mutations in MAP2K4, a JNK pathway kinase (shown in Figures 4C-E) resulted in a significant increase in anchorage-independent growth. Interestingly, these mutants exhibited reduced kinase activity compared to wild type MAP2K4, indicating these mutations impose a dominant-negative influence to promote growth (Figure 4F). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in *eLife*. DOI: 10.7554/eLife.11566.001

Introduction Human cancer is driven by the acquisition of mutations in cells of somatic origin. Somatic mutations comprise several distinct classes of DNA sequence changes, including single-nucleotide substitutions, small insertions and deletions (indels), copy number alterations, and structural rearrangements (Weir et al., 2007; Chin and Gray, 2008; Stratton et al., 2009; Pleasance et al., 2010). Somatic mutations can be further characterized based on their oncogenic ability: genetic variations that are directly involved in cancer development are termed "driver" mutations, whereas mutations that do not confer any obvious advantage are referred to as "passenger" mutations (Davies et al., 2005). In all cases, genetic changes in somatic cells arise as a result of defective DNA repair mechanisms and/or imprecise DNA replication, and can develop spontaneously, be acquired over the lifetime of an individual, or by direct exposure to mutagens, such as tobacco smoke and ionizing UV radiation (Pfeifer, 2010; Pleasance et al., 2010; Hellday et al., 2014). Over the past 10 years, technologies for the detection of wide-spread genetic alterations have been developed and used to analyze
cancer genomes (Stratton et al., 2009; Watson et al., 2013). Its is clear that cancer cell genomes often harbor substantial somatic mutation burdens, thus the ability to generate a comprehensive genetic cancer profile has the potential to significantly improve patient diagnosis and treatment.

The combination of PCR and Sanger sequencing to identify mutations in tumor genomes has proven to be a powerful approach in the study of cancer genomics (Collins et al., 2003). However, this technology is constrained by limited throughput and cost (Chin et al., 2011). Here, Kan and colleagues utilized mismatch repair detection (MRD) technology as a low-cost, high-throughput alternative to identify somatic mutations in a large number of primary human tumor samples (Peters et al., 2007). Using this technique, Kan and colleagues identified an uncharacterized somatic mutation in GNAO1 from breast carcinoma tissue (Kan et al., 2010). GNAO1 encodes the Gαo subunit of heterotrimeric guanine-binding proteins (G proteins) (Jastrzebska, 2013). G proteins function as molecular switches that alternate between "on" (GTP-bound) and "off" (GDP-bound) states to control signal transduction in eukaryotes (Gilman, 1987; Birnbaumer, 2007b, 2007a). While previous studies have reported oncogenic mutations in the Gα subunits of other G proteins, including GNAs, GNAI2 and GNAQ (Landis et al., 1989; Lyons et al., 1990; Forbes et al., 2008; Van Raamsdonk et al., 2009), the arginine 243 to histidine (R243H) conversion identified in GNAO1 does not correspond to any previously described mutations within G proteins (Garcia-Marcos et al., 2011). In Figure 3D–F, the oncogenic potential of this mutation was tested. Human mammary epithelial cells (HMECs) stably expressing equivalent levels of wild type GNAO1 or GNAO1R243H were suspended in agar before assessment for colony formation. This key experiment reported that the R243H mutation promotes a two-fold increase in anchorage-independent growth compared to cells expressing wild type GNAO1, and will be replicated in Protocol 1. Subsequent work on GNAO1 has characterized the molecular basis underlying the oncogenic properties of the R243H mutation. Importantly, these studies have determined that the R243H mutation renders Gαo constitutively active via Src-STAT3 signaling (Garcia-Marcos et al., 2011; Leyme et al., 2014).

Kan and colleagues also identified a number of somatic mutations in mitogen-activated protein kinase kinase 4 (MAP2K4) (Kan et al., 2010). MAP2K4 is a component of a triple kinase cascade that involves the successive activation of downstream MAP kinases, culminating in the activation of c-Jun NH2-terminal kinases (JNK) and p38 (Derijard et al., 1995; Chang and Karin, 2001; Johnson and Lapadat, 2002). Both the JNK and p38 signaling pathways mediate cellular responses to cytokine signals, stress and other extracellular stimuli (Johnson and Lapadat, 2002). While mutations in MAP2K4 have been reported here (Kan et al., 2010) and elsewhere (Teng et al., 1997; Parsons et al., 2005; Greenman et al., 2007; Forbes et al., 2008), the role of MAP2K4 in cancer has remained complex and contradictory. Some studies have suggested MAP2K4 functions as a pro-oncogenic molecule in breast and pancreatic tumors (Wang et al., 2004), melanoma (Finegan and Tournier, 2010), and in prostate cancer tumors (Lotan et al., 2007; Pavese et al., 2014), whereas other early reports identified MAP2K4 as a putative tumor suppressor gene due to its frequent inactivation in human cancer cell lines and tumor tissues, including pancreatic, breast, ovarian, and colon cancer cells and tissues (Su et al., 1998; 2002; Nakayama et al., 2006; Ahn et al., 2011).

In Figure 4C–E, the functional relevance of six select MAP2K4 mutants (5 located in the kinase domain, 1 outside the kinase domain) were tested in vitro (Kan et al., 2010). NIH3T3 fibroblasts stably expressing equivalent levels of either WT or mutant MAP2K4 were assessed for their ability to promote anchorage-independent growth. Importantly, all six MAP2K4 variants resulted in significantly enhanced agar colony formation compared to cells expressing wild type MAP2K4. A majority of the MAP2K4 mutants resulted in reduced activity to either JNK or myelin basic protein (MBP) when tested in an in vitro kinase assay suggesting that reduced MAP2K4 signaling plays a dominant-negative role in the control of cell growth. A related study examined the invasiveness of cells where endogenous MAP2K4 was depleted and various MAP2K4 mutants were added back, including four of the mutants tested by Kan and colleagues (Ahn et al., 2011). The effect on invasion was directly proportional to the kinase activities of the mutants. The mutations that resulted in loss-of-function kinase activity (including R154W, S251N, and N234I examined by Kan and colleagues) resulted in increased invasion, while mutations with gain-of-function kinase activity, or comparable kinase activity to wild-type (including A279T examined by Kan and colleagues), did not (Ahn et al., 2011). More recent studies have confirmed these findings, showing that MAP2K4 genetic inactivation is prevalent in high grade serous and endometrioid carcinomas, breast cancer, and pancreatic cancer (Davis et al., 2011; Yeasmin et al., 2011b; Yeasmin et al., 2011a; Curtis et al., 2012;
Furthermore, genetic polymorphisms that increase MAP2K4 promoter activity are associated with reduced risk of prostate, lung, and sporadic colorectal cancers (Wei et al., 2009; Liu et al., 2010; Shao et al., 2012). A recent study by Haeusgen and colleagues (Haeusgen et al., 2014) suggests that the balance between MAP2K4 and a novel MAP2K4 splice variant may be important in regulating appropriate cell growth. The key experiments described in Figures 4C–F will be replicated in Protocol 2.

Materials and methods

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (#) indicates information provided by the replicating lab.

Protocol 1: Generation of N-terminally Flag-tagged MAP2K4 and GNAO1 wild-type and mutant vectors

This protocol generates N-terminally flag-tagged wild type or mutant GNAO1 and wild type or mutant MAP2K4 vectors. These vectors will be used in Protocols 2 and 4.

Sampling

- This experiment will be performed once in order to generate vectors.

Materials and reagents

| Reagent | Type | Manufacturer | Catalog # | Comments |
|---------|------|--------------|-----------|----------|
| pRetroX-IRES-ZsGreen1 Vector | Plasmid | Clontech | 632520 | Original product number not specified; replaces pRetro-IRES-GFP-Vector |
| MAP2K4WT Myc-DDK tagged –includes FLAG tag | Plasmid | Origene | RC206051 | Original product number not specified |
| GNAO1WT Myc-DDK tagged (Variant 1) – includes FLAG tag | Plasmid | Origene | RC217958 | Original product number not specified |
| Agilent - QuikChange Lightning Multi Site-Directed Mutagenesis Kit | Kit | Agilent | 210516 | Original product number not specified |

1DDK is equivalent to FLAG which is a registered trademark of Sigma Aldrich

Procedure

1. 1. Generate GNAO1 and MAP2K4 mutant constructs:
   a. Perform site-directed mutations on cDNA ORFs using #Agilent QuikChange Kit according to manufacturer’s protocol.
      i. Point mutations:
         1. GNAO1: arginine 243 to histidine (R243H)
         2. MAP2K4: arginine 228 to lysine (R228K)
         3. MAP2K4: alanine 279 to threonine (A279T)
   b. #Perform PCR cloning using primers that encompass the ORF and FLAG-tag insert from the original cDNA

2. Clone inserts (includes FLAG tag) into #pRetroX-IRES-ZsGreen1 vector backbone according to manufacturer’s protocols.
   a. Specific molecular cloning steps and reagents used will be recorded and reported later.
   b. #Perform PCR cloning using primers that encompass the ORF and FLAG-tag insert from the original cDNA

3. Sequence vectors to confirm identity as well as mutational status, and run on gel to confirm integrity. [additional QC]
   a. #Use the following sequencing primers:
      i. GNAO1R243H Forward: GCCCTTTTTGAGTTTGAGTACC
      ii. GNAO1R243H Reverse: GTAAAGCATGTCAGGAGG
      iii. MAP2K4R228K Forward: GCCCTTTTTGAGTTTGAGTACC
      iv. MAP2K4R228K Reverse: GTAAAGCATGTCAGGAGG
      v. MAP2K4A279T Forward: GCCCTTTTTGAGTTTGAGTACC
      vi. MAP2K4A279T Reverse: GTAAAGCATGTCAGGAGG
Deliverables
- Data to be collected
  - Sequencing information and gel verification of vectors

- Sample delivered for further analysis:
  - Plasmids for use in Protocols 2 and 4:
    - pRetroX-IRES-ZsGreen1
    - pRetroX-FLAG-GNAO1\textsuperscript{WT}-IRES-ZsGreen1
    - pRetroX-FLAG-GNAO1\textsuperscript{R243H}-IRES-ZsGreen1
    - pRetroX-FLAG-MAP2K4\textsuperscript{WT}-IRES-ZsGreen1
    - pRetroX-FLAG-MAP2K4\textsuperscript{R228K}-IRES-ZsGreen1
    - pRetroX-FLAG-MAP2K4\textsuperscript{A279T}-IRES-ZsGreen1

Confirmatory analysis plan
- None applicable.

Known differences from the original study
The vector backbone pRetroX-IRES-ZsGreen1 will be used instead of pRetroX-IRES-FLAG because the latter is no longer available. The replicating lab will use a cDNA with an ORF tagged with myc-DDK (the same as FLAG) for downstream protocols. Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

Provisions for quality control
Sequencing and gel analysis of plasmids will be reported. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/jpeeq/) and made publically available.

Protocol 2: Generation of human mammary epithelial cells stably expressing wild-type or GNAO1\textsuperscript{R243H}
This protocol describes the generation of HMECs stably expressing WT or mutant GNAO1\textsuperscript{R243H} protein. Expression of GNAO1 will be confirmed by Western blot that will be a replication of Figure 3F. These cells will subsequently be used in Protocol 3.

Sampling
- This experiment to be conducted one time to confirm stable expression of GNAO1\textsuperscript{WT} or GNAO1\textsuperscript{R243H} protein.
- The experiment has 4 cohorts:
  - Cohort 1: Uninfected HMECs [additional negative control]
  - Cohort 2: HMECs transduced with pRetroX-IRES-ZsGreen1 -empty vector [additional negative control]
  - Cohort 3: HMECs transduced with pRetroX-FLAG-GNAO1\textsuperscript{WT}-IRES-ZsGreen1
  - Cohort 4: HMECs transduced with pRetroX-FLAG-GNAO1\textsuperscript{R243H}-IRES-ZsGreen1
- Western blotting will be performed for the following proteins:
  - FLAG
  - β-ACTIN

Materials and reagents

| Reagent                     | Type               | Manufacturer | Catalog # | Comments |
|-----------------------------|--------------------|--------------|-----------|----------|

Continued on next page
| Reagent | Type & Description | Manufacturer | Catalog # | Comments |
|---------|-------------------|--------------|-----------|----------|
| pRetroX-IRES-ZsGreen1 vector | Plasmid | Produced in Protocol 1 | |
| pRetroX-FLAG-GNAO1<sup>WT</sup>-IRES-ZsGreen1 vector | Plasmid | Produced in Protocol 1 | |
| pRetroX-FLAG-GNAO1<sup>R243H</sup>-IRES-ZsGreen1 vector | Plasmid | Produced in Protocol 1 | |
| HMECs | Cell line | ATCC | PCS-600-010 | Original product number not specified; Replaces Life Technology brand used in original study |
| HMEC medium | Cell culture | ATCC | PCS-600-03 | Original product number not specified; Replaces Life Technology brand used in original study |
| HMEC supplement | Cell culture | ATCC | PCS-600-040 | Original product number not specified; Replaces Life Technology brand used in original study |
| Bovine pituitary extract | Cell culture | Life Technologies | 13028014 | |
| Penicillin/Streptomycin | Cell culture | Applied Biological Materials | G255 | Original not specified |
| Phoenix amphoteric cells | Cell line | ATCC | ATCC CRL-3213 | Replaces Orbigen brand used in original study |
| DMEM | Cell culture | Sigma | 11965-092 | Original not specified |
| Fetal bovine serum (FBS) | Cell culture | Life Technologies | 12483-020 | Original not specified |
| L-glutamine | Cell culture | Life Technologies | 35050-061 | Original not specified |
| Glucose | Cell culture | Life Technologies | A2494001 | Original not specified |
| Lipofectamine 2000 | Transfection Reagent | Life Technologies | 11668027 | |
| Opti-MEM | Transfection Reagent | Sigma-Aldrich | 31985070 | Original not specified |
| PBS | Buffer | GIBCO | 10010023 | Original not specified |
| 0.45 μm syringe filter | Labware | Millipore | SLHV033RB | Original not specified |
| Trypsin EDTA | Buffer | ABM | TM050 | Original not specified |
| FBS | Buffer | GIBCO | 12483 | Original not specified |
| SDS | Chemical | Left to the discretion of the replicating lab | |
| 2-mercaptoethanol | Chemical | | | |
| Glycerol | Chemical | | | |
| bromophenol blue | Chemical | | | |
| Tris-HCl | Chemical | | | |
| Bradford Assay | Detection assay | Sigma | B6916-500 ML | Original not specified |
| 12% SDS-PAGE gel | Western Blot Reagent | Invitrogen | EC60252BOX | Original 4–20% |
| OptiProtein Marker | Western Blot Reagent | Applied Biological Materials | G252 | Original not specified |
| PVDF membrane | Western Blot Reagent | Biorad | 162-0015 | Original Nitrocellulose |
| Skim milk powder | Western Blot Reagent | Fisher Scientific | 361021617 | Original not specified |
| 1X TBS solution | Buffer | Fisher Scientific | BP2471-100 | Original not specified |
| Anti-FLAG M2 antibody | Antibody | Sigma | F1804 | |
| Anti-B-ACTIN antibody | Antibody | Abcam | Ab8227 | Original not specified |
| Anti-mouse HRP-conjugated secondary antibody | Antibody | Abcam | Ab6728 | Original not specified |
| ECL Reagent A and B | Western Blot Reagent | Applied Biological Materials | G075 | Replaces Thermo Fisher brand |
| X-ray Film | Western Blot Reagent | Kodak | XBT-1 | Original not specified |

**Procedure**

**Notes:**

Sharma *et al.* eLife 2016;5:e11566. DOI: 10.7554/eLife.11566
HMECs are grown in complete HMEC medium: HMEC medium supplemented with HMEC supplement, 0.05 mg/mL bovine pituitary extract, 100 U/mL penicillin and 100 mg/ml streptomycin cultured at 37°C and 5% CO₂.

Phoenix cells are grown in complete DMEM medium: DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 4.5 g/L glucose, 100 U/mL penicillin and 100 mg/ml streptomycin cultured at 37°C and 5% CO₂.

All cells will be sent for mycoplasma testing and STR profiling.

1. **Transfect Phoenix cells with the appropriate retroviral constructs using Lipofectamine 2000 according to manufacturer’s instructions.**
   a. On the day before transfection, transfer Phoenix cells to fresh medium in 6 well plates and maintain at 37°C and 5% CO₂.
   b. On the day of transfection, dilute 2.5 μg plasmid DNA in 500 μl Opti-MEM medium and mix gently.
      i. pRetroX-FLAG-GNAO1WT-IRES-ZsGreen1
      ii. pRetroX-FLAG-GNAO1R243H-IRES-ZsGreen1
      iii. pRetroX-IRES-ZsGreen1 (empty vector)
   c. Incubate for 30 min at room temperature.
   d. Add DNA-Opti-MEM mixture to 500 μl Lipofectamine 2000.
   e. Add DNA-Lipofectamine LTX complex to wells containing Phoenix cells and mix gently
   f. Incubate cells for 18–48 hr.
      i. Change media after 4–6 hr to complete media containing serum.
   g. Harvest virus-containing supernatants 48 hr post transfection and re-feed cells with DMEM. Incubate at 37°C in a humidified 5% CO₂ incubator. Note: Multiple rounds of collection may be required for concentrating stock.
      i. This initial collected media can be stored briefly at 4°C.
   h. After an additional 12–24 hr of culture, collect viral supernatants again and pool with first collection.
      i. **Concentrate viral stock.**
         i. Centrifuge the viral supernatant at 3000 rpm for 15 min to remove any cell debris.
         ii. Filter the supernatant through a 0.45 μm syringe filter.
         iii. Ultracentrifuge at 22,000 rpm for 2 hr at 4°C to produce concentrated viral stocks.
         iv. Aliquot virus into screw-cap centrifuge tubes and store at -70°C.
   j. **Titre retrovirus**
      i. One day before harvesting viral supernatant, plate 1.2 × 10⁵ HMECs per well of a 6 well dish.
      ii. On the day of viral supernatant harvesting, count the number of cells in one well to determine cell number at time of infection.
      iii. Add a range of volumes between 2 to 5 μl of concentrated viral supernatant to the wells. Incubate for 72 hr.
      iv. Remove culture medium, wash the wells once with 2 ml PBS.
      v. Add 0.5 ml of 0.25% trypsin EDTA
      vi. Incubate 5 min at 37°C.
      vii. Add 0.5 ml DMEM-10 or 15 (10–15% FBS).
      viii. Pipette up and down with 1 ml pipette and transfer cells to a FACS tube.
      ix. Determine the percentage of GFP-positive cells by FACS analysis.
      x. Calculate the number of transfection units (TU/ml):
         1. Divide the % GFP-positive cells by 100.
         2. Multiply that by the number of cells at the time of infection
         3. Divide that number by the volume of the virus added (ml)
         4. This will yield the number of viral particles per ml.
   k. Use resulting virus to transduce HMECs in Step 3.

2. **One day prior to transduction, seed HMECs in 15 cm plates so they will be 70–90% confluent on the day of transfection.**

3. **Transduce HMECs with the appropriate viruses (Optimal MOI will be determined prior to transduction).**
   1. Infect HMECs on a 24-well plate with lentivirus.
      i. Cohort 1: Uninfected HMECs [additional negative control]
      ii. Cohort 2: HMECs transduced with pRETRO-IRES-ZsGreen1-empty vector [additional negative control]
iii. Cohort 3: HMECs transduced with pRETRO-FLAG-GNAO1<sup>WT</sup>-IRES-ZsGreen1
iv. Cohort 4: HMECs transduced with pRETRO-FLAG-GNAO1<sup>R243H</sup>-IRES-ZsGreen1

2. After 72 hr, check cells under fluorescence microscope to calculate infection rate.

4. *Sterile sort the top 10% of the transduced HMECs by *<sup>§</sup>flow cytometry based on GFP expression.
   a. Trypsinize the cells and resuspend in PBS with 0.5% FBS (FACS buffer)
   b. Pass the cells through the cell strainer to make a single cell suspension.
   c. Sort cells for GFP signal (top 10% selected) on FACS sorter (Influx 100 μm-18 psi)
      i. 100,000 cells are collected per tube.

5. *Perform Western blots on top 10% GFP positive HMECs to confirm expression of GNAO1:
   a. Spin down the cells for 5 min at maximum speed using an eppendorf tube centrifuge. Aspirate and discard the supernatant.
   b. Add 100 μl to 200 μl of protein lysis buffer depending on the size of the cell pellet.
      i. *Protein lysis buffer: 4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl pH 6.8
      ii. Quantify protein concentration using a *Bradford assay according to manufacturer’s instructions.
   c. Load equal amounts of total protein in 25 μl sample on a *<sup>12%</sup> SDS-PAGE gel.
      i. Boil for 7 min before loading
      ii. Load one lane with 8 μl protein marker ladder.
      iii. Run at 150V for 10-15 min.
      iv. When samples reach separation gel, turn to 100V and run for approximately 1.5 hr. Record running time.
   d. Wet transfer to *<sup>§</sup>PVDF membrane *at 95V for 70 min.
   e. *Block membrane with 3% skim milk in Tris-buffered saline (TBS) on shaker for 30 min
   f. Incubate with the following primary antibodies for 1 hr at 37°C:
      i. Mouse Anti-FLAG M2 (1:500 dilution)
      ii. *Mouse Anti-β-ACTIN (*1:1000 dilution)
   g. Wash membrane 3 times in 1X TBS for 5 min each on shaker.
   h. Incubate with anti-mouse HRP conjugated secondary antibody (*1:1000) for 1 hr on shaker at room temperature.
      i. Remove membrane from secondary antibody and wash three times in 1X TBS for 5 min each.
   j. Prepare ECL solution and incubate membrane.
   k. Expose membrane to X-ray film, develop and scan.

Deliverables

• Data to be collected:
  • Data for viral titration
  • Flow cytometry data (for viral titration and sorting of transduced cells)
  • Protein determination assay data.
  • Figure 3F: Full scans of all films for each western blot with ladder.
• Sample delivered for further analysis:
  • HMECs transduced with:
    • pRetroX-IRES-ZsGreen1 (empty vector)
    • pRetroX-FLAG-GNAO1<sup>WT</sup>-IRES-ZsGreen1
    • pRetroX-FLAG-GNAO1<sup>R243H</sup>-IRES-ZsGreen1

Confirmatory analysis plan

• None applicable.

Known differences from the original study

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. GNAO1 expression will be confirmed in the top 10% GFP positive HMECs with western blots. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/jpeqg/) and made publically available.

Protocol 3: Anchorage-independent colony formation assay of HMECs transduced with wild-type or mutant GNAO1
This experiment tests the effect of WT or mutant GNAO1 expression on anchorage-independent colony formation of HMECs. It is a replication of the experiments reported in Figure 3D–E.

Sampling
- Experiment to be repeated a total of 3 times for a power of 99%.
  - See Power Calculations section for details.
- Experiment has 4 cohorts:
  - Cohort 1: Uninfected HMECs [additional negative control]
  - Cohort 2: HMECs transduced with pRetroX-IRES-ZsGreen1-empty vector [additional negative control]
  - Cohort 3: HMECs transduced with pRetroX-FLAG-GNAO1WT-IRES-ZsGreen1
  - Cohort 4: HMECs transduced with pRetroX-FLAG-GNAO1R243H-IRES-ZsGreen1
- Each cohort will have anchorage independent colony formation quantified.

Materials and reagents

| Reagent                                      | Type      | Manufacturer | Catalog # | Comments                                                                 |
|----------------------------------------------|-----------|--------------|-----------|---------------------------------------------------------------------------|
| HMECs                                        | Cell line | ATCC         | PCS-600-010 | Original product number not specified; Replaces Life Technology brand used in original study |
| HMECs transduced with pRetroX-IRES-ZsGreen1-empty vector | Cell line | Produced in Protocol 2 |           |                                                                           |
| HMECs transduced with pRetroX-FLAG-GNAO1WT-IRES-ZsGreen1 | Cell line | Produced in Protocol 2 |           |                                                                           |
| HMECs transduced with pRetroX-FLAG-GNAO1R243H-IRES-ZsGreen1 | Cell line | Produced in Protocol 2 |           |                                                                           |
| HMEC medium                                  | Cell culture | ATCC       | PCS-600-03 | Replaces Life Technology brand used in original study                      |
| HMEC supplement                              | Cell culture | ATCC       | PCS-600-040 | Original product number not specified; Replaces Life Technology brand used in original study |
| Bovine pituitary extract                     | Cell culture | Life Technologies | 13028014 | Original not specified                                                     |
| Penicillin/streptomycin                      | Cell culture | ABM     | G255 | Original not specified                                                     |
| 6 well plates                                | Labware    | Fisher Scientific | Biolite 12556004 | Original not specified                                                     |
| Low melting temperature agar                 | Cell culture | Bioworld | 40100048-2 | Original not specified                                                     |
| Crystal violet                               | Dye       | Left to the discretion of the replicating lab | Not originally used |
| Methanol (MeOH)                              | Chemical  | NIH          |           | Replaces Oxford Optronix GelCount imager and software                     |
| Acetic acid                                  | Chemical  |             |           |                                                                           |

Procedure
Notes:
- Transduced HMECs are generated in Protocol 2.
1. Grow 3 flasks of transduced and untransduced control HMECs in complete HMEC medium: HMEC medium supplemented with HMEC supplement, 0.5 mg/mL bovine pituitary extract, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO₂ (these will be the biological replicates).

2. Plate a lower layer of 1 ml 0.5% agar per well in twelve wells of 6-well plates.
   a. Let solidify.

3. Suspend 3 wells each of 3 x 10⁴ HMECs in 1 ml full media containing 0.35% agar containing either:
   a. untransduced HMECs
   b. HMECs transduced with pRetroX-IRES-ZsGreen1 (empty vector)
   c. HMECs transduced with pRetroX-FLAG-GNAO1<sub>WT</sub>-IRES-ZsGreen1
   d. HMECs transduced with pRetroX-FLAG-GNAO1<sub>R243H</sub>-IRES-ZsGreen1

4. Plate 1 ml suspended cells on top of the lower layer of 0.5% agar in 6-well plates.

5. Incubate the plates for 3 weeks at 37°C and 5% CO₂.
   a. Refresh growth media on top layer every 2–3 days.

6. Assess the presence of colonies.
   a. Stain wells with crystal violet.
      1. Remove media from wells.
      2. Fix with 500 μl of 10% MeOH/10% acetic acid for 10 min.
      3. Remove and wash with 500 μl 0.01% crystal violet for 1 hr.
      4. Remove stain and wash wells.
   b. Image entire well with high-resolution camera.
      1. Include calibration scale in image.
   c. Quantify the number of colonies greater than 200 μm in diameter using ImageJ software.
      1. Set threshold using calibration scale taken during image acquisition.

Deliverables
- Data to be collected:
  - Figure 3D: Images of colonies.
  - Raw numbers for quantification of colonies for each sample.
  - Figure 3E: Graph of mean number of colonies for each cohort.

Confirmatory analysis plan
- Statistical Analysis of the Replication Data:
  - Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.
  - Unpaired two-tailed t-test of the mean number of colonies in HMECs expressing exogenous GNAO1<sub>WT</sub> or GNAO1<sub>R243H</sub>.
  - Meta-analysis of original and replication attempt effect sizes:
    - This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

Known differences from the original study
The original study counted cell colonies using GelCount to image, count, and analyze colonies, while the replication attempt will stain with crystal violet to enhance detection of cell colonies, image wells with a high-resolution camera, and use ImageJ software to count and analyze colonies. Since the software and approach used by the original and replication attempt are different, there will likely be some differences in sensitivity and error rates. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/jpeqg/) and made publicly available.

Protocol 4: Generation of NIH3T3 cells stably expressing wild-type or mutant MAP2K4
This protocol describes the generation of NIH3T3 cells stably expressing wild-type or mutant MAP2K4 proteins. This protocol also describes verification of expression of MAP2K4 by western blot that will be a replication of Figure 4E. These cells will subsequently be used in Protocols 4 and 5.

Sampling
- This experiment will be conducted one time to confirm stable expression of exogenous MAP2K4.
- Experiment has 5 cohorts:
  - Cohort 1: Uninfected NIH3T3 cells [additional negative control]
  - Cohort 2: transduced with pRetroX-IRES-ZsGreen1 (empty vector)
  - Cohort 3: transduced with pRetroX-FLAG-MAP2K4^{WT}-IRES-ZsGreen1
  - Cohort 4: transduced with pRetroX-FLAG-MAP2K4^{R228K}-IRES-ZsGreen1
  - Cohort 5: transduced with pRetroX-FLAG-MAP2K4^{A279T}-IRES-ZsGreen1
- To confirm MAP2K4 expression, Western blotting will be performed for the following proteins:
  - FLAG
  - β-ACTIN [Additional loading control]

Materials and reagents

| Reagent                      | Type              | Manufacturer             | Catalog #  | Comments                                           |
|------------------------------|-------------------|--------------------------|------------|----------------------------------------------------|
| NIH3T3 cells                 | Cell line         | ATCC                     | CRL-1658   |                                                    |
| DMEM medium                  | Cell culture      | Sigma                    | 11965-092  | Original not specified                             |
| FBS                          | Cell culture      | Life Technologies       | 12483-020  | Original not specified                             |
| L-glutamine                  | Cell culture      | Life Technologies       | 35050-061  | Original not specified                             |
| Penicillin/Streptomycin      | Cell culture      | Applied Biological Materials | G255   | Original not specified                             |
| pRetroX-IRES-ZsGreen1 vector | Plasmid           | Produced in Protocol 1   |            |                                                    |
| pRetroX-FLAG-MAP2K4^{WT}-IRES-ZsGreen1 vector | Plasmid | Produced in Protocol 1   |            |                                                    |
| pRetroX-FLAG-MAP2K4^{R228K}-IRES-ZsGreen1 vector | Plasmid | Produced in Protocol 1   |            |                                                    |
| pRetroX-FLAG-MAP2K4^{A279T}-IRES-ZsGreen1 vector | Plasmid | Produced in Protocol 1   |            |                                                    |
| Phoenix amphoteric cells     | Cell line         | ATCC                     | ATCC CRL-3213 | Replaces Orbigen brand used in original study       |
| Lipofectamine 2000           | Transfection Reagent | Life Technologies     | 11668027   |                                                    |
| Opti-MEM                     | Transfection Reagent | Sigma-Aldrich         | 31985070   | Original not specified                             |
| PBS                          | Buffer            | GIBCO                    | 10010023   | Original not specified                             |
| 0.45 μm syringe filter       | Labware           | Millipore                | SLHVI033RB | Original not specified                             |
| Trypsin EDTA                 | Buffer            | ABM                      | TM050      | Original not specified                             |
| FBS                          | Buffer            | GIBCO                    | 12483      | Original not specified                             |
| SDS                          | Chemical          |                          |            |                                                    |
| 2-mercaptoethanol            | Chemical          |                          |            |                                                    |
Continued

| Reagent            | Type                    | Manufacturer        | Catalog #   | Comments                |
|--------------------|-------------------------|---------------------|-------------|-------------------------|
| Glycerol           | Chemical                |                     |             |                         |
| bromophenol blue   | Chemical                |                     |             |                         |
| Tris-HCl           | Chemical                |                     |             |                         |
| Bradford Assay     | Detection assay         | Sigma               | B6916-500 ML| Original not specified  |
| 12% SDS-PAGE gel   | Western Blot Reagent    | Invitrogen          | EC60252BOX  | Original 4–20%          |
| OptiProtein Marker | Western Blot Reagent    | Applied Biological Materials | G252 | Original not specified  |
| PVDF membrane      | Western Blot Reagent    | Biorad              | 162-0015    | Original Nitrocellulose |
| 1X TBS solution    | Buffer                  | Fisher Scientific   | BP2471-100  |                         |
| Anti-FLAG M2 antibody | Antibody              | Sigma               | F1804       |                         |
| Anti-ß-ACTIN antibody | Antibody              | Abcam               | Ab8227      | Original not specified  |
| Anti-mouse HRP-conjugated secondary antibody | Antibody | Abcam | Ab6728 | Original not specified |
| ECL Reagent A and B | Western Blot Reagent    | Applied Biological Materials | G075 | Replaces Thermo Fisher brand. |
| X-ray Film         | Western Blot Reagent    | Kodak               | XBT-1       | Original not specified  |

Procedure

Notes:

- NIH3T3 cells are grown in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO₂.
- Phoenix cells grown in complete DMEM medium: DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO₂.
- All cells will be sent for mycoplasma testing and STR profiling.

1. Transfect Phoenix cells with the appropriate constructs as in Protocol 2 step 1.
2. Transduce NIH3T3 cells with the appropriate viruses as in Protocol 2 steps 2 and 3.
3. Sterile sort the top 10% of the transduced NIH3T3 cells by flow cytometry based on GFP expression as in Protocol 2 Step 4.
4. Perform western blot on sorted cells to confirm expression of MAP2K4 as in Protocol 2 Step 5.

Deliverables

- Data to be collected:
  - Data for viral titration
  - Flow cytometry data (for viral titration and sorting of transduced cells)
  - Protein determination assay data.
  - Figure 4E: Full scans of all films for each western with ladder.
- Sample delivered for further analysis:
  - NIH3T3 cells transduced with:
    - pRetroX-IRES-ZsGreen1 (empty vector)
    - pRetroX-FLAG-MAP2K4WT-IRES-ZsGreen1
    - pRetroX-FLAG-MAP2K4R228K-IRES-ZsGreen1
    - pRetroX-FLAG-MAP2K4A279T-IRES-ZsGreen1

Confirmatory analysis plan

- None applicable.

Known differences from the original study

Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents.

Sharma et al. eLife 2016;5:e11566. DOI: 10.7554/eLife.11566
section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

Provisions for quality control
The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. MAP2K4 expression will be confirmed in the top 10% GFP positive HMECs with Western blots. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/jpeqg/) and made publicly available.

Protocol 5: Anchorage-independent colony formation assay of NIH3T3 cells transduced with wild-type or mutant MAP2K4
This experiment tests the effect of WT or mutant MAP2K4 expression on anchorage-independent colony formation of NIH3T3 cells. It is a replication of the experiments reported in Figure 4C and 4D.

Sampling
- Experiment to be repeated a total of 3 times for a minimum power of 99%.
- See Power Calculations section for details.
- Experiment has 5 (generated in Protocol 4) cohorts:
  - Cohort 1: Uninfected NIH3T3 cells [additional negative control]
  - Cohort 2: NIH3T3 cells transduced with with pRetroX-IRES-ZsGreen1-empty vector
  - Cohort 3: NIH3T3 cells transduced with with pRetroX-FLAG-MAP2K4\textsuperscript{WT}-IRES-ZsGreen1
  - Cohort 4: NIH3T3 cells transduced with with pRetroX-FLAG-MAP2K4\textsuperscript{R228K}-IRES-ZsGreen1
  - Cohort 5: NIH3T3 cells transduced with with pRetroX-FLAG-MAP2K4\textsuperscript{A279T}-IRES-ZsGreen1
- Each cohort will have anchorage independent colony formation quantified.

Materials and reagents

| Reagent | Type                | Manufacturer           | Catalog #   | Comments               |
|---------|---------------------|------------------------|-------------|------------------------|
| NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1-empty vector | Cell line | Produced in Protocol 4 |             |
| NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4\textsuperscript{WT}-IRES-ZsGreen1 | Cell line | Produced in Protocol 4 |             |
| NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4\textsuperscript{R228K}-IRES-ZsGreen1 | Cell line | Produced in Protocol 4 |             |
| NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4\textsuperscript{A279T}-IRES-ZsGreen1 | Cell line | Produced in Protocol 4 |             |
| DMEM medium | Cell culture | Sigma | 11965-092 | Original not specified |
| FBS | Cell culture | Life Technologies | 12483-020 | Original not specified |
| L-glutamine | Cell culture | Life Technologies | 35050-061 | Original not specified |
| Penicillin/streptomycin | Cell culture | Applied Biological Materials | G255 | Original not specified |
| 6 well plates | Labware | Fisher Scientific | Biolite 12556004 | Original not specified |
| Low melting temperature agar | Cell culture | Bioworld | 40100048-2 | Original not specified |
| Crystal violet | Dye | Left to the discretion of the replicating lab | Not originally used |
| Methanol (MeOH) | Chemical | | | |
| Acetic acid | Chemical | | | |
| ImageJ | Software | NIH | | Replaces Oxford Optronix GelCount imager and software |

Procedure
Note:
All cells will be sent for mycoplasma testing and STR profiling.

1. Grow 3 flasks each of transduced NIH3T3 cells generated in Protocol 4 in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO₂. (these will be the biological replicates)

2. Plate a lower layer of #1 ml 0.5% agar per well in 16 wells of 6-well plates.
   a. Let solidify.

3. Suspend 3 plates each of 1 x 10⁴ cells/plate in 1 ml full media containing 0.35% agar containing either:
   - uninfected NIH3T3 cells [additional negative control]
   - NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1-empty vector
   - NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4⁷⁸₄WT-IRES-ZsGreen1
   - NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4R²²⁸K-IRES-ZsGreen1
   - NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4⁹²³⁴⁴⁸⁴⁷₄A²⁷⁹T-IRES-ZsGreen1

4. Plate #1 ml suspended cells on top of the lower layer of 0.5% agar in 6-well plates.

5. Incubate the plates for 3 weeks at 37°C and 5% CO₂.
   a. Refresh growth media from top layer every 2–3 days.

6. Assess the presence of colonies.
   a. Stain wells with crystal violet.
      1. Remove media from wells.
      2. Fix with 500 µl of 10% MeOH/10% acetic acid for 10 min.
      3. Remove and stain with 500 µl 0.01% crystal violet for 1 hr.
      4. Remove stain and wash wells.
   b. Image entire well with a high-resolution camera.
      1. Include calibration scale in image.
   c. Quantify the number of colonies greater than 100 µm in diameter using ImageJ software.
      1. Set threshold using scale taken during image acquisition.

Deliverables
- Data to be collected:
  - Figure 4C: Images of colonies.
  - Raw numbers for quantification of colonies for each sample.
  - Figure 4D: Graph of mean number of colonies for each cohort.

Confirmatory analysis plan
- Statistical Analysis of the Replication Data:
  - Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.
  - One-way ANOVA of the mean number of colonies in NIH3T3 cells expressing exogenous MAP2K4⁷⁸₄WT, MAP2K4R²²⁸K, or MAP2K4A²⁷⁹T followed by planned comparisons using Fisher's LSD:
    - MAP2K4⁷⁸₄WT vs MAP2K4R²²⁸K
    - MAP2K4⁷⁸₄WT vs MAP2K4A²⁷⁹T
  - Meta-analysis of original and replication attempt effect sizes:
    - Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

Known differences from the original study
Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. The original study counted cell colonies using GelCount to image, count, and analyze colonies, while the replication attempt will stain with crystal violet to enhance detection of cell colonies, image wells with a high-resolution camera, and use ImageJ software to
count and analyze colonies. Since the software and approach used by the original and replication attempt are different, there will likely be some differences in sensitivity and error rates. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/jpeqg/) and made publically available.

Protocol 6: Assessing the kinase activity of wild-type or mutant MAP2K4
This experiment tests the in vitro kinase activity of WT or mutant MAP2K4 immunoprecipitated from NIH3T3 cells. It is a replication of the experiment reported in Figure 4F.

Sampling
- Experiment to be repeated a total of 4 times.
  - The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes were determined based on a range of potential variance.
  - See Power Calculations section for details.
- Experiment has 5 cohorts:
  - Cohort 1: Uninfected NIH3T3 cells [additional negative control]
  - Cohort 2: NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1 (empty vector)
  - Cohort 3: NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4WT-IRES-ZsGreen1
  - Cohort 4: NIH3T3 cells transduced pRetroX-FLAG-MAP2K4R228K-IRES-ZsGreen1
  - Cohort 5: NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4A279T-IRES-ZsGreen1
- A kinase assay is performed for each cohort using the following substrates:
  - Myelin basic protein (MBP)
  - Inactive MAPK9/JNK2

Materials and reagents

| Reagent | Type | Manufacturer | Catalog #   | Comments                  |
|---------|------|--------------|-------------|---------------------------|
| NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1-empty vector | Cell line | Produced in Protocol 4 |                        |
| NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4WT-IRES-ZsGreen1 | Cell line | Produced in Protocol 4 |                        |
| NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4R228K-IRES-ZsGreen1 | Cell line | Produced in Protocol 4 |                        |
| NIH3T3 cells transduced with pRetroX-FLAG-MAP2K4A279T-IRES-ZsGreen1 | Cell line | Produced in Protocol 4 |                        |
| DMEM medium | Cell culture | Sigma | 11965-092 | Original not specified |
| FBS | Cell culture | Life Technologies | 12483-020 | Original not specified |
| L-glutamine | Cell culture | Life Technologies | 35050-061 | Original not specified |
| EZview FLAG-M2-antibody-coupled affinity gel | Chromatography | Sigma | A2220 |                        |
| Penicillin/streptomycin | Cell culture | Applied Biological Materials | G255 | Original not specified |
| Cell Lysis Buffer | Buffer | Cell Signaling Technology | 9803 | Original product number not specified |

Continued on next page
Continued

| Reagent | Type                          | Manufacturer                  | Catalog # | Comments                                      |
|---------|-------------------------------|-------------------------------|-----------|-----------------------------------------------|
| PMSF    | Protease inhibitor            | Cell Signaling Technology     | 8853      | Original not specified                        |
| Myelin basic protein | Protein                      | Signalchem                   | M42-51N   | Replaces Millipore AB15542                    |
| Inactive MAPK9/JNK2 | Protein                      | Invitrogen                   | PV3621    | Listed as MAPK7 in original paper.            |
| γ-32P]ATP | Chemical                     | Perkin Elmer                  | BLU002H250UC |                              |
| Kinase Reaction Buffer | Buffer                       | Cell Signaling Technology     | 9802      | Original product number not specified         |
| Anti-FLAG M2 Magnetic Beads | Kinase assay reagent           | Sigma-Aldrich                 | M8823     | Original not specified                        |
| 12% SDS-PAGE | Western Blot Reagent          | Invitrogen                   | EC60252BOX | Original 4–20%                                |
| Bradford Assay | Detection assay               | Sigma                         | B6916-500 ML | Original not specified                        |
| OptiProtein Marker | Western Blot Reagent          | Applied Biological Materials  | G252      | Original not specified                        |
| PVDF membrane | Western Blot Reagent          | Biorad                        | 162-0015  | Original Nitrocellulose                       |
| Skim milk powder | Western Blot Reagent         | Fisher Scientific            | 361021617 | Original not specified                        |
| 1X TBS solution | Buffer                       | Fisher Scientific            | BP2471-100 | Original not specified                        |
| Anti-FLAG M2 antibody | Antibody                      | Sigma                         | F1804     | Original not specified                        |
| Anti-β-ACTIN antibody | Antibody                     | Abcam                         | Ab8227    | Original not specified                        |
| Anti-mouse HRP-conjugated secondary antibody | Antibody                   | Abcam                         | Ab6728    | Original not specified                        |
| ECL Reagent A and B | Western Blot Reagent         | Applied Biological Materials  | G075      | Replaces Thermo Fisher brand.                 |
| X-ray Film | Western Blot Reagent          | Kodak                         | XBT-1     | Original not specified                        |

Procedure

Note:
- Transduced NIH3T3 cells are generated in Protocol 4.
- All cells will be sent for mycoplasma testing and STR profiling.

1. Grow 4 flasks of NIH3T3 in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin cultured at 37°C and 5% CO₂. These are the biological replicates.
2. Generate cell lysates:
   a. Plate cells for kinase assay so they will be 70–90% confluent on the day of harvest.
   b. Replace with serum free media (0% FBS) and serum starve cells for 24 hr.
   c. Wash cells with PBS and lyse with Cell Lysis Buffer (with 1 mM PMSF added just before use).
   d. Clarify lysates.
   e. Quantify protein concentration using a Bradford Assay according to manufacturer’s instructions.
   f. Adjust samples to equalize for total amount of protein and concentration.
3. Perform immunoprecipitation:
   a. Incubate clarified lysates with anti-FLAG-M2 conjugated beads overnight at 4°C.
   b. Spin beads down at 10,000xg for 30 s, remove supernatant and wash three times with Cell lysis buffer (with 1 mM PMSF added just before use).
   c. Remove sample for input analysis and divide sample equally between two microcentrifuge tubes.
   d. Spin beads down and remove supernatant.
4. Kinase Assay
   a. Add 25 µl of Kinase Reaction Buffer supplemented with 10 µM ATP and 2 µCi [γ-32P]ATP with either:
      i. Myelin basic protein (MBP) (*1:2000)
      ii. Inactive MAPK9/JNK2 (*1:2000).
b. Incubate samples for 30 min at 30°C.
c. Stop kinase reactions by adding SDS sample buffer.
d. Resolve kinase reactions on 15% SDS-PAGE gel with protein ladder.
e. Fix gel for 15 min in 5% methanol, 7% acetic acid and dry at 60°C for 30 min.
f. Expose gel to X-ray film and scan images.

5. Perform western blot on input sample for MAP2K4 expression as in Protocol 2 Step 5.
6. For each replicate normalize each protein (MBP and MAPK9/JNK2) to MAP2K4 input levels and then normalize each sample to MAP2K4WT.

Deliverables
- Data to be collected:
  - Protein determination assay data.
  - Figure 4F: Full images of autoradiographs for each kinase assay substrate with ladder.
  - Figure 4F: Scans of full films for western blot of MAP2K4 input with ladder.

Confirmatory analysis plan
- Statistical Analysis of the Replication Data:
  - Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.
  - Bonferroni corrected one-sample t-tests of normalized pMBP levels from the following MAP2K4 variants compared to 1 (MAP2K4WT):
    - MAP2K4R228K
    - MAP2K4A279T
  - Bonferroni corrected one-sample t-tests of normalized pMAPK9/pJNK levels from the following MAP2K4 variants compared to 1 (MAP2K4WT):
    - MAP2K4R228K
    - MAP2K4A279T
- Meta-analysis of effect sizes:
  - Since some of the band intensities in the original paper were unable to be quantified the replication study will record and make accessible all autoradiographs collected. This will allow for a subjective comparison of the original images and the replication images. Additionally, the replication will quantify the results in an additional exploratory measure. This cannot be compared to the original reported results, but will be presented to understand the utility of analyzing the data in a quantitative manner.

Known differences from the original study
Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/jpeqq/) and made publicly available.

Power calculations
For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:
Protocol 1:
- Not applicable

Protocol 2:
- Not applicable

Protocol 3:
Summary of original data
- Note; values are from data shared by authors, which was reported in Figure 3E.

| Vector | Mean # of colonies >200 μm diameter | Stdev    | N |
|--------|-------------------------------------|----------|---|
| WT     | 113.5                               | 10.607   | 2 |
| R243H  | 201.5                               | 16.263   | 2 |

Test family
- Two-tailed t test, difference between two independent means, alpha error = 0.050

Power calculations
- Performed with G*Power software, version 3.1.7 (Faul et al., 2007).

| Group 1 | Group 2 | Effect size d | A priori power | Group 1 sample size | Group 2 sample size |
|---------|---------|----------------|----------------|---------------------|---------------------|
| WT      | R243H   | 6.40954        | 87.2%          | 2^1                 | 2^1                 |

1 3 samples per group will be used making the achieved power of 99.9%.
2 The calculation was also performed with the non-parametric Wilcoxon-Mann-Whitney test, which gives an achieved power of 99.9% with a sample size of 3 per group.

Protocol 4:
- Not applicable

Protocol 5:
Summary of original data
- Note: values are from data shared by authors, which was reported in Figure 4D:

| Vector | Mean # of colonies >100 μm diameter | Stdev    | N  |
|--------|-------------------------------------|----------|----|
| WT     | 16                                  | 2.8284   | 2  |
| R228K  | 36                                  | 2.8284   | 2  |
| A279T  | 94.5                                | 7.7782   | 2  |
Test family

- ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05

Power calculations

- Performed with G*Power software, version 3.1.7 (Faul et al., 2007).
- ANOVA F test statistic and partial $\eta^2$ performed with R software, version 3.1.2 (Team, 2014).

| Groups | F test statistic | Partial $\eta^2$ | Effect size $f$ | A priori power | Total sample size |
|--------|-----------------|-----------------|-----------------|----------------|------------------|
| NIH3T3 cells transduced with WT or MAP2K4 mutants | $F_{(2,3)} = 130.52$ | 0.98864 | 9.3280 | 99.9% | $6^1$ |

$^1$9 total samples (3 per group) will be used as a minimum sample size making the power 99.9%.

Test family

- Two-tailed t test, difference between two independent means, Fisher’s LSD: alpha error = 0.05

Power calculations

- Performed with G*Power software, version 3.1.7 (Faul et al., 2007).

| Group 1 | Group 2 | Effect size $d$ | A priori power | Group 1 sample size | Group 2 sample size |
|---------|---------|-----------------|----------------|---------------------|---------------------|
| WT      | R228K   | 7.07107         | 99.9%$^{1,2}$ | $2^1$               | $2^1$               |
| WT      | A279T   | 13.4134         | 99.9%$^{1,2}$ | $2^1$               | $2^1$               |

$^1$ 3 samples per group will be used making the power 99.9%.
$^2$ The calculation was also performed with the non-parametric Wilcoxon-Mann-Whitney test, which gives an achieved power of 99.9% with a sample size of 3 per group.

**Protocol 6**

**Summary of original data**

- Note: data estimated from the image reported in Figure 4F.
  - The original data presented is qualitative (images of Western blots). We used ImageJ version 1.50a (Schneider et al., 2012) to perform densitometric analysis of the presented bands to quantify the original effect size where possible. The data presented in Figure 4F for Input MAP2K4 were unable to be quantified for all bands and were thus excluded from the normalization. Additionally, the WT values provide under-estimates of the actual values since the WT bands were saturated and unable to be quantified.

| Variant | Normalized pJNK band intensity to WT | Normalized pMBP band intensity to WT |
|---------|-------------------------------------|--------------------------------------|
| WT      | 1                                   | 1                                    |
| R228K   | 0.299736                            | 0.057556                             |
| A279T   | 0.613378                            | 0.096804                             |

- The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.
Test family

- t-test: Means: Difference from constant (one sample case): Bonferroni’s correction: alpha error = 0.0125.

Power calculations

- Performed with G*Power software, version 3.1.7 (Faul et al., 2007).
- 2% variance

| Substrate | Variant | Constant (WT) | Effect size $d$ | A priori power | Sample size per group |
|-----------|---------|---------------|-----------------|----------------|-----------------------|
| P-JNK     | R228K   | 1             | 116.813         | 99.9%          | 3                     |
|           | A279T   | 1             | 31.5157         | 99.9%          | 3                     |
| P-MBP     | R228K   | 1             | 818.713         | 99.9%          | 3                     |
|           | A279T   | 1             | 466.507         | 99.9%          | 3                     |

- 15% variance

| Substrate | Variant | Constant (WT) | Effect size $d$ | A priori power | Sample size per group |
|-----------|---------|---------------|-----------------|----------------|-----------------------|
| P-JNK     | R228K   | 1             | 15.5751         | 99.9%          | 3                     |
|           | A279T   | 1             | 4.20210         | 92.2%          | 4                     |
| P-MBP     | R228K   | 1             | 109.162         | 99.9%          | 3                     |
|           | A279T   | 1             | 62.2009         | 99.9%          | 3                     |

- 28% variance

| Substrate | Variant | Constant (WT) | Effect size $d$ | A priori power | Sample size per group |
|-----------|---------|---------------|-----------------|----------------|-----------------------|
| P-JNK     | R228K   | 1             | 8.34380         | 92.6%          | 3                     |
|           | A279T   | 1             | 2.25112         | 88.7%          | 6                     |
| P-MBP     | R228K   | 1             | 58.4795         | 99.9%          | 3                     |
|           | A279T   | 1             | 33.3219         | 99.9%          | 3                     |

- 40% variance

| Substrate | Variant | Constant (WT) | Effect size $d$ | A priori power | Sample size per group |
|-----------|---------|---------------|-----------------|----------------|-----------------------|
| P-JNK     | R228K   | 1             | 5.84066         | 99.5%          | 4                     |
|           | A279T   | 1             | 1.57579         | 82.5%          | 8                     |
| P-MBP     | R228K   | 1             | 40.9357         | 99.9%          | 3                     |
|           | A279T   | 1             | 23.3254         | 99.9%          | 3                     |

- Based on these ranges of variance, which use a conservative effect size estimate since the original data were unable to be quantified, we will run the experiment four times.
Acknowledgements

The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Bijay Jaiswal, for generously sharing critical information to ensure the fidelity and quality of this replication attempt. We are grateful to Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).

Additional information

Group author details

Reproducibility Project: Cancer Biology

Elizabeth Iorns: Science Exchange, Palo Alto, United States; William Gunn: Mendeley, London, United Kingdom; Fraser Tan: Science Exchange, Palo Alto, United States; Joelle Lomax: Science Exchange, Palo Alto, United States; Nicole Perfito: Science Exchange, Palo Alto, United States; Timothy Errington: Center for Open Science, Charlottesville, United States

Competing interests

VS, LY the experiments presented in this manuscript will be conducted at Applied Biological Materials, which is a Science Exchange lab. RP:CB employed by and holds shares in Science Exchange Inc. The other authors declare that no competing interests exist.

Funding

Funder Author
Laura and John Arnold Foundation The Reproducibility Project: Cancer Biology Core Team

The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

VS, LY, ABA, KO, Drafting or revising the article; RP:CB, Conception and design, Drafting or revising the article

References

Ahn Y-H, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilanganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. 2011. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor 2 expression. Molecular and Cellular Biology 31:4270–4285. doi: 10.1128/MCB.05562-11

Birnbaumer L. 2007a. The discovery of signal transduction by G proteins. a personal account and an overview of the initial findings and contributions that led to our present understanding. Biochimica Et Biophysica Acta 1768:756–771. doi: 10.1016/j.bbamem.2006.09.027

Birnbaumer L. 2007b. Expansion of signal transduction by G proteins. The second 15 years or so: from 3 to 16 alpha subunits plus betagamma dimers. Biochimica Et Biophysica Acta 1768:772–793. doi: 10.1016/j.bbamem.2006.12.002

Chang L, Karin M. 2001. Mammalian MAP kinase signalling cascades. Nature 410:37–40. doi: 10.1038/35065000

Chin L, Gray JW. 2008. Translating insights from the cancer genome into clinical practice. Nature 452:553–563. doi: 10.1038/nature06914

Chin L, Hahn WC, Getz G, Meyerson M. 2011. Making sense of cancer genomic data. Genes & Development 25:534–555. doi: 10.1101/gad.2017311

Collins FS, Green ED, Guttmacher AE, Guyer MS. US National Human Genome Research Institute. 2003. A vision for the future of genomics research. Nature 422:835–847. doi: 10.1038/nature01626
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samaraiwja S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerørd A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Barresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S. METABRIC Group. 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352. doi: 10.1038/10983

Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O’Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clintons J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Braeus F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Research 65:7591–7595. doi: 10.1158/0008-5472.CAN-05-1885

Davis SJ, Choong DYH, Ramakrishna M, Ryland GL, Campbell IG, Gorringe KL. 2011. Analysis of the mitogen-activated protein kinase kinase 4 (mAP2K4) tumor suppressor gene in ovarian cancer. BMC Medicine 11:173. doi: 10.1186/1741-7015-11-173

Derijard B, Raingeaud J, Barrett T, Wu I, Han J, Ulevitch R, Davis R. 1995. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267:682–685. doi: 10.1126/science.7839144

Ewing JM, Iorns E, Gunn W, Tan FE, Lomax J, Nosek BA. 2014. An open investigation of the reproducibility of cancer biology research. eLife 3. doi: 10.7554/eLife.04333

Faul F, Erdfelder E, Lang A-G, Buchner A. 2007. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 39:175–191. doi: 10.3758/BF03193146

Finegan KG, Tournier C. 2010. The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Research 70:5797–5806. doi: 10.1158/0008-5472.CAN-09-3669

Forbes SA, Bhama R, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. 2008. The catalogue of somatic mutations in cancer (cOSMIC). Current Protocols in Human Genetics 10. doi: 10.1002/0471249050.sg11051s7

Garcia-Marcos M, Ghosh P, Farquhar MG. 2011. Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene 30:2691–2696. doi: 10.1038/onc.2010.645

Gillman AG. 1987. G proteins: transducers of receptor-generated signals. Annual Review of Biochemistry 56:615–649. doi: 10.1146/annurev.bi.56.070187.003151

Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhry B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Braeus F, Looijenga L, Weber BL, Chiew Y-E, deFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Nature 431:568–572. doi: 10.1038/nature02927

Haeusgen W, Tueffers L, Herdegen T, Waetzig V, waetzig, v. 2014. Map2k4â—identification and functional characterization of a novel Map2k4 splice variant. Biochimica Et Biophysica Acta 1843:875–884. doi: 10.1016/j.bbamcr.2014.01.028

Helleday T, Eshtad S, Nik-Zainal S. 2014. Mechanisms underlying cancer genome instability. Nature Reviews Genetics 15:585–598. doi: 10.1038/nrg3729

Huang L, Wu C, Yu D, Wang C, Che X, Miao X, Zhai K, Chang J, Jiang G, Yang X, Cao G, Hu Z, Zhou Y, Zuo C, Wang C, Zhang X, Zhou Y, Yu X, Dai W, Li Z, Shen H, Liu L, Chen Y, Zhang S, Wang X, Liu Y, Sun M, Cao W, Gao J, Ma Y, Zheng X, Cheung ST, Jia Y, Tan W, Wu T, Lin D. 2013. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Carcinogenesis 34:1001–1005. doi: 10.1093/carcin/bgt004

Jastrzebska B. 2013. GPCR: g protein complexes—the fundamental signaling assembly. Amino Acids 45:1303–1314. doi: 10.1007/s00726-013-1593-y

Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 299:1911–1912. doi: 10.1126/science.1072682

Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Hawerty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VEH, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Research 65:7591–7595. doi: 10.1158/0008-5472.CAN-05-1885

Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. 1989. GTPase inhibiting mutations activate the α chain of gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692–696. doi: 10.1038/340692a0

Leyme A, Marivin A, Casler J, Nguyen LT, Garcia-Marcos M. 2014. Different biochemical properties explain why two equivalent g subunit mutants cause unrelated diseases. Journal of Biological Chemistry 289:21818–21827. doi: 10.1074/jbc.M114.549790
Liu B, Chen D, Yang L, Li Y, Ling X, Liu L, Ji W, Wei Y, Wang J, Wei Q, Wang L, Lu J. 2010. A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity. Carcinogenesis 31:1405–1411. doi: 10.1093/carcin/bgq126

Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W, Rinker-Schaeffer CW. 2007. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. The Journal of Pathology 212:386–394. doi: 10.1002/path.2194

Lyon J, Labranda C, Harsh G, Vallar L, Gronewald K, Feichtinger H, Duh Q, Clark O, Kawasaki E, Bourne H, et al. 1990. Two g protein oncogenes in human endocrine tumors. Science 249:655–659. doi: 10.1126/science.2116665

Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih le-Ming, Wang T-L. 2006. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biology & Therapy 5:630–634. doi: 10.4161/cbt.5.6.2675

Parsons DW, Wang T-L, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. 2005. Colorectal cancer: mutations in a signalling pathway. Nature 436:792. doi: 10.1038/436792a

Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B, Bergan RC, Tang C-H. 2014. Mitogen-activated protein kinase kinase 4 (mAP2K4) promotes human prostate cancer metastasis. PLoS ONE 9:e102289. doi: 10.1371/journal.pone.0102289

Peters BA, Kan Z, Sebisanovic D, Pujara K, Wang Z, Hong P, Chow B, Stinson J, Carlton VEH, Pham TQ, Stern H, Waring P, Hillan KJ, Eberhard DA, de Sauvage F, Zheng J, Fahim M, Seshagiri S. 2007. Highly efficient somatic-mutation identification using escherichia coli mismatch-repair detection. Nature Methods 4:713–715. doi: 10.1038/nmeth1081

Pfeifer GP. 2010. Environmental exposures and mutational patterns of cancer genomes. Genome Medicine 2:54. doi: 10.1186/gm175

Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, Lin M-L, Beare D, Lau KW, Greenman C, Vareila N, Zifal S, Davies H, Ordoñez GR, Mudie LJ, Latimer C, Ekins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mongion J, Sun YA, Maughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA, Campbell PJ. 2010. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184–190. doi: 10.1038/nature08629

Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH image to ImageJ: 25 years of image analysis. Nature Methods 9:671–675. doi: 10.1038/nmeth.2089

Shao N, Wang Y, Lu K, Jiang W-Y, Li Q, Wang N, Feng N-H, Hua L-X. 2012. Role of the functional MKK4 promoter variant (-1304T>G) in a decreased risk of prostate cancer: case–control study and meta-analysis. Journal of Cancer Research and Clinical Oncology 138:1531–1539. doi: 10.1007/s00432-012-1226-y

Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458:719–724. doi: 10.1038/nature07943

Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH, Kern SE. 1998. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Research 58:2339–2342.

Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. 2002. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Human Mutation 19:81. doi: 10.1002/humu.9002

Team RC. 2014. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.

Teng DH, Perry WL, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, Janecki T, Leavitt A, Mitchell JT, Pero R, Sexton D, Schroeder M, Su PH, Swedlund B, Kyriakis JM, Avruch J, Bartel P, Wong AK, Tavtigian SV. 1997. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Research 57:4177–4182.

Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC. 2009. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599–602. doi: 10.1038/nature07586

Wang L, Pan Y, Dai JL. 2004. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 23:5978–5985. doi: 10.1080/01620880410001707802

Watson IR, Takahashi K, Futreal PA, Chin L. 2013. Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics 14:703–718. doi: 10.1038/nrg3539

Wei Y, Wang L, Lan P, Zhao H, Pan Z, Huang J, Lu J, Wang J. 2009. The association between -1304T>G polymorphism in the promoter of MKK4 gene and the risk of sporadic colorectal cancer in southern chinese population. International Journal of Cancer. Journal International Du Cancer 125:1876–1883. doi: 10.1002/ijc.24575

Weir BA, Woo MS, Getz G, Pernier S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fuji Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rustch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao M-S, Twomey D, Verhaak RGW, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE,

Sharma et al. eLife 2016;5:e11566. DOI: 10.7554/eLife.11566

22 of 23
Wilson RK, Lander ES, Meyerson M. 2007. Characterizing the cancer genome in lung adenocarcinoma. *Nature* **450**:893–898. doi: 10.1038/nature06358

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K. 2011. Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. *International Journal of Cancer* **128**:94–104. doi: 10.1002/ijc.25332

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K. 2011. MKK4 acts as a potential tumor suppressor in ovarian cancer. *Tumor Biology* **32**:661–670. doi: 10.1007/s13277-011-0166-5